Quarterly report [Sections 13 or 15(d)]

SCHEDULE OF SEGMENT INFORMATION (Details)

v3.26.1
SCHEDULE OF SEGMENT INFORMATION (Details) - USD ($)
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Product Information [Line Items]    
Net Revenue $ 1,351,527 $ 1,853,597
Total operating loss (3,616,976) (2,627,139)
Non-operating income (expense), net (13,634) (24,583)
Net loss before income taxes (3,630,610) (2,651,722)
Income tax expense (8,695)
Net loss (3,630,610) (2,660,417)
Diagnostic R&D [Member]    
Product Information [Line Items]    
Net Revenue 1,131
Total operating loss (683,747) (505,739)
Laboratory Services [Member]    
Product Information [Line Items]    
Net Revenue 1,350,396 1,853,597
Total operating loss (1,832,592) (2,267,656)
General Corporate Activities [Member]    
Product Information [Line Items]    
Total operating loss $ (2,452,164) $ (1,707,341)